These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22293020)

  • 1. Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
    Ferreiro JL; Cequier AR; Angiolillo DJ
    Trends Cardiovasc Med; 2010 Oct; 20(7):211-7. PubMed ID: 22293020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.
    Capranzano P; Capodanno D
    Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):307-17. PubMed ID: 23469911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.
    Ferreiro JL; Cequier ÁR; Angiolillo DJ
    Diab Vasc Dis Res; 2010 Oct; 7(4):274-88. PubMed ID: 20921091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus.
    Angiolillo DJ; Roffi M; Fernandez-Ortiz A
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):697-710. PubMed ID: 21714601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in responsiveness to oral antiplatelet therapy.
    Angiolillo DJ
    Am J Cardiol; 2009 Feb; 103(3 Suppl):27A-34A. PubMed ID: 19166710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
    Bernlochner I; Byrne RA; Kastrati A; Sibbing D
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel.
    Curzen N
    Heart; 2012 Nov; 98(22):1617-9. PubMed ID: 22801999
    [No Abstract]   [Full Text] [Related]  

  • 10. Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
    El-Menyar A; AlHabib KF; Al-Motarreb A; Hersi A; Al Faleh H; Asaad N; Al Saif S; Almahmeed W; Sulaiman K; Amin H; Al-Lawati J; Alsheikh-Ali AA; AlQahtani A; Al-Sagheer NQ; Singh R; Al Suwaidi J
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):127-35. PubMed ID: 22257172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
    Angiolillo DJ; Suryadevara S
    Best Pract Res Clin Endocrinol Metab; 2009 Jun; 23(3):375-88. PubMed ID: 19520310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
    Aronow WS
    Postgrad Med; 2013 Jan; 125(1):51-8. PubMed ID: 23391671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study.
    De Luca G; Secco GG; Iorio S; Verdoia M; Bellomo G; Marino P
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):756-9. PubMed ID: 23135381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
    Vavalle JP; Rao SV
    Adv Cardiol; 2012; 47():125-40. PubMed ID: 22906908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Geng DF; Liu M; Jin DM; Wu W; Deng J; Wang JF
    Cardiology; 2012; 122(3):148-57. PubMed ID: 22832561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
    Collet JP; Montalescot G
    Int J Cardiol; 2009 Mar; 133(1):8-17. PubMed ID: 19187982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.